Jaguar Health Inc.

10/01/2024 | Press release | Distributed by Public on 10/01/2024 06:41

Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.